Belumosudil (1) – Rezurock®
Chronic graft-versus-host disease (cGvHD), aged ≥ 12 years, weighing ≥ 40 kg
Characteristics
| Start date | 01.05.2026 |
|---|---|
| Resolution | 15.10.2026 – active procedure |
| INN | Belumosudil |
| Brand name | Rezurock® |
| Pharm. company | Sanofi-Aventis Deutschland GmbH |
| G-BA Procedure ID | D-1317 |
| Therapeutic area | Oncological diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions